Eli Lilly has significantly expanded its artificial intelligence capabilities through a series of high-profile initiatives designed to accelerate drug discovery and enhance R&D efficiency. In September, it launched TuneLab, a free AI-driven drug discovery platform for smaller biotech firms, securing data-sharing agreements that enrich Lilly’s proprietary datasets. The following month, Lilly formed a strategic partnership with Nvidia to develop the industry’s most powerful pharmaceutical AI supercomputer, aimed at reducing the time required to identify viable drug candidates. Earlier this month, the company opened a joint AI drug discovery lab in the San Francisco Bay Area, co-staffed by Lilly’s researchers and Nvidia engineers, with the goal of shortening research timelines by leveraging machine learning models to predict molecule efficacy and safety.

In its most recent quarter, Eli Lilly reported revenue of $17.60 billion, representing a 53.9 percent year-over-year increase, and delivered earnings per share of $7.02, beating consensus by $0.60. The company’s net margin stood at 30.99 percent, while return on equity reached 109.52 percent. For fiscal 2025, Lilly issued EPS guidance of $23.00 to $23.70, reflecting confidence in continued top-line growth driven by leadership in the weight-loss market and a diversified late-stage pipeline spanning neuroscience, immunology and oncology. The board also approved a dividend increase to $1.73 per share, implying a 29.35 percent payout ratio and demonstrating commitment to returning capital to shareholders.

Eli Lilly’s share register is dominated by institutional holders, which collectively own over 82 percent of outstanding shares. In the third quarter, First Citizens Bank & Trust Co. boosted its stake by 58.8 percent, adding 9,121 shares to reach a 24,634-share position valued at $18.8 million. Meanwhile, Commerzbank Aktiengesellschaft FI reduced its holdings by 1.8 percent to 39,787 shares, reflecting active portfolio rebalancing rather than a shift in conviction. A series of smaller hedge funds and wealth managers also initiated or expanded positions during the period, underscoring broad confidence among professional investors in Lilly’s long-term growth trajectory.